33 results
6-K
EX-99.1
MOR
Morphosys AG
30 Apr 24
First Quarter Interim Statement January – March 2024
8:57am
and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts … the overall competence profile based on their professional competence, experience, integrity, commitment, independence, and character. Proposals
6-K
EX-99.1
MOR
Morphosys AG
13 Mar 24
Current report (foreign)
4:08pm
, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B and 2B, who were not TD at baseline … , experience, integrity, commitment, independence, and character. Proposals to the Annual The Company Group Management Report Financial Statements Additional
6-K
EX-99.1
MOR
Morphosys AG
16 Nov 23
Half-Year Report JANUARY – JUNE
9:25am
) status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12
6-K
EX-99.1
7ht 8br77ttv
16 Nov 23
Third Quarter Interim Statement JANUARY – SEPTEMBER 2023
6:00am
6-K
EX-99.1
u8x s9kyjbsr6
2 Nov 23
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
9:20am
6-K
EX-99.1
yv9s9tmbm
10 Aug 23
Half-Year Report JANUARY – JUNE 2023
8:51am
6-K
EX-99.1
bvaoewuoehu 828
14 Jun 23
Current report (foreign)
7:28am
6-K
EX-99.1
h74bwvqc2uhsmi
11 May 23
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
1:12pm
6-K
EX-99.1
djhgmv9
4 May 23
First Quarter Interim Statement January – March
9:24am
6-K
EX-99.1
fl1pfiphg1kxv
4 Apr 23
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
4:09pm
6-K
EX-99
85t4kzmhbe 5w6
12 Dec 22
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
6:04am
6-K
EX-99.1
881ns
16 Nov 22
Third Quarter Interim Statement January – September
4:14pm
6-K
EX-99.1
87sfsp9fub91
3 Nov 22
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
9:40am
6-K
EX-99.1
sx7jqda6db6tgkxx
3 Aug 22
Half-Year Report JANUARY – JUNE 2022
4:36pm
6-K
EX-99.1
3cpd1ut g1gr4us
23 Jun 22
First Quarter Interim Statement JANUARY – MARCH
6:30am
6-K
EX-99.1
6wojc cpe
10 Jun 22
Current report (foreign)
7:16am
6-K
EX-99.1
c047h vy27t
23 Mar 22
Current report (foreign)
4:15pm
6-K
EX-99.1
gmm7bk0
16 Mar 22
Current report (foreign)
5:13pm